Aurobindo-Sandoz deal pushed back as FTC seeks more info

Nov. 7, 2019

According to an Economic Times report, an inquiry from the U.S. Federal Trade Commission has delayed Aurobindo Pharma’s acquisition of the Sandoz's dermatology and generics business. The FTC is reportedly seeking more information on a lawsuit that Aurobindo is facing.

The closure of the acquisition has been delayed to next year as a result of the inquiry, with February being reported as the earliest possible date.

Novartis originally announced back in September 2018 that it will sell its Sandoz U.S. dermatology business and generic U.S. oral solids portfolio to India’s Aurobindo Pharma for up to $1 billion.

Read the full Economic Times report